The biomarker landscape in mycosis fungoides and Sézary syndrome

Brittany Dulmage, Larisa Geskin, Joan Guitart, Oleg E. Akilov*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

Original languageEnglish (US)
Pages (from-to)668-676
Number of pages9
JournalExperimental Dermatology
Issue number8
StatePublished - Aug 2017


  • cell surface marker
  • cutaneous T-cell lymphoma
  • gene expression
  • screening
  • secretory protein

ASJC Scopus subject areas

  • Dermatology
  • Molecular Biology
  • Biochemistry


Dive into the research topics of 'The biomarker landscape in mycosis fungoides and Sézary syndrome'. Together they form a unique fingerprint.

Cite this